Pivya
(Pivmecillinam)ApprovedSmall molecule
Pivya is one of 49 small molecule programs targeting Pyelonephritis. It is currently in Approved.
3
Indications
5
Total Trials
3
Active Trials
48
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
39 competitors in Urinary Tract Infection
#DrugCompanyPhaseTrials
1Doribax
ShionogiApproved
Cipro
BayerApproved
Levaquin
WWim Janssens
Approved
Ivadantin
PProcter and Gamble
Approved
Estrace
Novo NordiskApproved
Voltaren
NovartisApproved
Acanya
PfizerApproved
Vesicare
AstellasApproved
Invanz
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Monurol
MMeitheal
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Urinary Tract Infection1 trial
Antibiotic Prophylaxis1 trial
Effectiveness1 trial
Clinical Effectiveness and Bacteriological Eradication of 4 Short-course Antibiotics for Uncomplicated UTIs in Women.
Completed·FFundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina·Phase 4·NCT04959331·1,000 enrolled
Regulatory
FDA Approval Timeline[4]
Apr 24, 2024
PIVYA
NDA NDA216483
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pivmecillinam. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- AAlembic Pharmaceuticals Ltd.